A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: 300622
• Study Type: interventional
• Target: 420
• Locations: 1 country
• Sites: 110

Brief Summary

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

Conditions

Irritable Bowel Syndrome

Keywords

Camlipixant; Irritable bowel syndrome - Mixed; Irritable bowel syndrome - Diarrhea; Dose Ranging

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Weekly Abdominal pain intensity (API) over Weeks 7 to 12

  Participants rate their pain intensity daily on a numeric rating scale from 0 (no pain) to 10 (worst possible pain). Weekly API scores are derived by averaging daily API scores. Higher score indicates worst outcome. A repeated measures statistical analysis is applied to weekly scores, and the result for the Weeks 7 to 12 interval is obtained by averaging adjusted mean estimates for Weeks 7, 8, 9, 10, 11 and 12.

  Baseline, Weeks 7 to 12 (time - average)

Secondary Outcomes (16)

• Change from Baseline in weekly abdominal score over Weeks 7 to 12

  Baseline, Weeks 7 to 12 (time - average)

• Percentage of API responders up to Week 12

  Up to Week 12

• Change from Baseline in Weekly API over Weeks 7 to 12 (IBS-D participants)

  Baseline, Weeks 7 to 12 (time - average)

• Change from Baseline in Bristol Stool Form Scale (BSFS) over Weeks 7 to 12 (IBS-D participants)

  Baseline, Weeks 7 to 12 (time - average)

• Percentage of API and Global Improvement Scale (GIS) responders (composite response) up to Week 12

  Baseline and up to Week 12

Study Arms (4)

Placebo/Placebo or Camlipixant

PLACEBO COMPARATOR

Participants will receive placebo in Part A and Placebo or Camlipixant in Part B.

Drug: Placebo; Drug: Camlipixant

Camlipixant dose level 1/Placebo or Camlipixant

EXPERIMENTAL

Participants will receive Camlipixant dose level 1 in Part A and Placebo or Camlipixant in Part B.

Drug: Placebo; Drug: Camlipixant

Camlipixant dose level 2/Placebo or Camlipixant

EXPERIMENTAL

Participants will receive Camlipixant dose level 2 in Part A and Placebo or Camlipixant in Part B.

Drug: Placebo; Drug: Camlipixant

Camlipixant dose level 3/Placebo or Camlipixant

EXPERIMENTAL

Participants will receive Camlipixant dose level 3 in Part A and Placebo or Camlipixant in Part B

Drug: Placebo; Drug: Camlipixant

Interventions

Placebo DRUG

Placebo to be administered

Camlipixant dose level 1/Placebo or Camlipixant; Camlipixant dose level 2/Placebo or Camlipixant; Camlipixant dose level 3/Placebo or Camlipixant; Placebo/Placebo or Camlipixant

Camlipixant DRUG

Camlipixant to be administered

Camlipixant dose level 1/Placebo or Camlipixant; Camlipixant dose level 2/Placebo or Camlipixant; Camlipixant dose level 3/Placebo or Camlipixant; Placebo/Placebo or Camlipixant

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged 18 to 80 years inclusive, at the time of signing the Informed consent form (ICF).
• Diagnosis of IBS-D or IBS-M according to the Rome IV criteria at screening
• Moderate or severe irritable bowel syndrome (IBS) based on Irritable bowel syndrome Severity Scoring System (IBS SSS) at screening visit
• Weekly API score \>=4.0 in each week of the run-in period
• IBS-D: at least one stool with BSFS Type 6 or 7 consistency on at least 2 days in each week of the run-in period
• IBS-M: an average of 2 days per week with abnormal bowel movements (BSFS Type 1, 2, 6, or 7) during the run-in period, and greater than (\>)25% of abnormal bowel movements must be Type 6 or 7 and \>25% Type 1 or 2

You may not qualify if:

• Diagnosis of Irritable bowel syndrome - constipation (IBS-C) or Irritable bowel syndrome - unclassified (IBS-U)
• History or presence of inflammatory or immune-mediated Gastrointestinal (GI) disorders e.g. inflammatory bowel disease, microscopic colitis, or celiac disease
• History or presence of GI infection (confirmed with stool culture) within 3 months prior to screening
• History or presence of bile salt diarrhea
• History of a primary psychiatric diagnosis that the Investigator considers may interfere with study assessments (e.g., schizophrenia, schizoaffective disorder, major depression, anxiety, panic attacks or bipolar disorder) OR Hospital Anxiety and Depression Scale (HADS) score of \>10 at screening.
• Prior use of more than two of the following therapies or classes of therapy for the management of IBS:
• Antidepressants or neuromodulators (e.g., Tricyclic antidepressant \[TCAs\], Selective serotonin reuptake inhibitor \[SSRIs\], gabapentinoids)
• Antibiotics (e.g., rifaximin, neomycin)
• hydroxytryptamine 3 (5-HT3) receptor antagonists (e.g., alosetron, ramosetron, ondansetron)
• Mu-opioid receptor agonists (e.g., eluxadoline)
• Secretagogues (e.g., linaclotide, lubiprostone, plecanatide, tenapanor)
• hydroxytryptamine 4 (5-HT4) receptor agonists (e.g., tegaserod)
• Abnormal thyroid function tests less than (\<) Lower limit of normal (LLN) or greater than (\>) upper limit of normal (ULN) confirmed at screening with Thyroid stimulating hormone (TSH)
• Positive celiac serology
• Elevated fecal calprotectin levels

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (110)

GSK Investigational Site

Anniston, Alabama, 36207, United States

RECRUITING

GSK Investigational Site

Guntersville, Alabama, 35976, United States

RECRUITING

GSK Investigational Site

Mobile, Alabama, 36608, United States

RECRUITING

GSK Investigational Site

Saraland, Alabama, 36571, United States

RECRUITING

GSK Investigational Site

Scottsdale, Arizona, 85260, United States

RECRUITING

GSK Investigational Site

Tempe, Arizona, 85284, United States

RECRUITING

GSK Investigational Site

Anaheim, California, 92804, United States

RECRUITING

GSK Investigational Site

Chula Vista, California, 91910, United States

RECRUITING

GSK Investigational Site

Coronado, California, 92118, United States

RECRUITING

GSK Investigational Site

Garden Grove, California, 92845, United States

RECRUITING

GSK Investigational Site

Lancaster, California, 93534, United States

RECRUITING

GSK Investigational Site

Lancaster, California, 93534, United States

RECRUITING

GSK Investigational Site

Los Angeles, California, 90015, United States

RECRUITING

GSK Investigational Site

Murrieta, California, 92563, United States

RECRUITING

GSK Investigational Site

Pasadena, California, 91105, United States

RECRUITING

GSK Investigational Site

San Diego, California, 92103, United States

RECRUITING

GSK Investigational Site

San Diego, California, 92120, United States

RECRUITING

GSK Investigational Site

Sherman Oaks, California, 91403, United States

RECRUITING

GSK Investigational Site

West Hills, California, 91307, United States

RECRUITING

GSK Investigational Site

Aurora, Colorado, 80012, United States

RECRUITING

GSK Investigational Site

Colorado Springs, Colorado, 80907, United States

RECRUITING

GSK Investigational Site

Lone Tree, Colorado, 80124, United States

RECRUITING

GSK Investigational Site

Brandon, Florida, 33511, United States

RECRUITING

GSK Investigational Site

Clearwater, Florida, 33756, United States

RECRUITING

GSK Investigational Site

Coral Gables, Florida, 33134, United States

RECRUITING

GSK Investigational Site

Doral, Florida, 33126, United States

RECRUITING

GSK Investigational Site

Hialeah, Florida, 33016, United States

RECRUITING

GSK Investigational Site

Homestead, Florida, 33033, United States

RECRUITING

GSK Investigational Site

Jacksonville, Florida, 32258, United States

RECRUITING

GSK Investigational Site

Kissimmee, Florida, 34741, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33126, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33134, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33144, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33145, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33157, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33165, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33173, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33174, United States

RECRUITING

GSK Investigational Site

Miami, Florida, 33186, United States

RECRUITING

GSK Investigational Site

Miami Beach, Florida, 33141, United States

RECRUITING

GSK Investigational Site

Miami Lakes, Florida, 33016, United States

RECRUITING

GSK Investigational Site

Miami Springs, Florida, 33166, United States

RECRUITING

GSK Investigational Site

New Port Richey, Florida, 34653, United States

RECRUITING

GSK Investigational Site

Ocala, Florida, 34471, United States

RECRUITING

GSK Investigational Site

Orlando, Florida, 32807, United States

RECRUITING

GSK Investigational Site

Orlando, Florida, 32835, United States

RECRUITING

GSK Investigational Site

Palm Harbor, Florida, 34684, United States

RECRUITING

GSK Investigational Site

Pembroke Pines, Florida, 33024, United States

RECRUITING

GSK Investigational Site

Pembroke Pines, Florida, 33026, United States

RECRUITING

GSK Investigational Site

Sunrise, Florida, 33351, United States

RECRUITING

GSK Investigational Site

Tampa, Florida, 33607, United States

RECRUITING

GSK Investigational Site

Tampa, Florida, 33607, United States

RECRUITING

GSK Investigational Site

Tampa, Florida, 33613, United States

RECRUITING

GSK Investigational Site

Tampa, Florida, 33614, United States

RECRUITING

GSK Investigational Site

Atlanta, Georgia, 30328, United States

RECRUITING

GSK Investigational Site

Atlanta, Georgia, 30342-5006, United States

RECRUITING

GSK Investigational Site

Decatur, Georgia, 30033, United States

RECRUITING

GSK Investigational Site

Lawrenceville, Georgia, 30044, United States

RECRUITING

GSK Investigational Site

Union City, Georgia, 30291, United States

RECRUITING

GSK Investigational Site

Meridian, Idaho, 83646, United States

RECRUITING

GSK Investigational Site

Morton, Illinois, 61550, United States

RECRUITING

GSK Investigational Site

Oak Lawn, Illinois, 60453, United States

RECRUITING

GSK Investigational Site

Ames, Iowa, 50010, United States

RECRUITING

GSK Investigational Site

Houma, Louisiana, 70360, United States

RECRUITING

GSK Investigational Site

Boston, Massachusetts, 02111, United States

RECRUITING

GSK Investigational Site

Flint, Michigan, 48504, United States

RECRUITING

GSK Investigational Site

Chesterfield, Missouri, 48038, United States

RECRUITING

GSK Investigational Site

Hazelwood, Missouri, 63042, United States

RECRUITING

GSK Investigational Site

Missoula, Montana, 59808, United States

RECRUITING

GSK Investigational Site

Hartsdale, New York, 10530, United States

RECRUITING

GSK Investigational Site

New Windsor, New York, 12553, United States

RECRUITING

GSK Investigational Site

New York, New York, 10016, United States

RECRUITING

GSK Investigational Site

North Massapequa, New York, 11758, United States

RECRUITING

GSK Investigational Site

Richmond Hill, New York, 11418, United States

RECRUITING

GSK Investigational Site

Rochester, New York, 14609, United States

RECRUITING

GSK Investigational Site

Charlotte, North Carolina, 28210, United States

RECRUITING

GSK Investigational Site

Fayetteville, North Carolina, 28304, United States

RECRUITING

GSK Investigational Site

Greenville, North Carolina, 27834, United States

RECRUITING

GSK Investigational Site

Rocky Mount, North Carolina, 27804, United States

RECRUITING

GSK Investigational Site

Salisbury, North Carolina, 28144, United States

RECRUITING

GSK Investigational Site

Winston-Salem, North Carolina, 27103, United States

RECRUITING

GSK Investigational Site

Beavercreek, Ohio, 45431, United States

RECRUITING

GSK Investigational Site

Columbus, Ohio, 43202, United States

RECRUITING

GSK Investigational Site

Mentor, Ohio, 44060, United States

RECRUITING

GSK Investigational Site

Norman, Oklahoma, 73071, United States

RECRUITING

GSK Investigational Site

Tulsa, Oklahoma, 74104, United States

RECRUITING

GSK Investigational Site

Harrisburg, Pennsylvania, 17110, United States

RECRUITING

GSK Investigational Site

Pittsburgh, Pennsylvania, 15236, United States

RECRUITING

GSK Investigational Site

Uniontown, Pennsylvania, 15401, United States

RECRUITING

GSK Investigational Site

Chattanooga, Tennessee, 37404, United States

RECRUITING

GSK Investigational Site

Chattanooga, Tennessee, 37412, United States

RECRUITING

GSK Investigational Site

Johnson City, Tennessee, 37604, United States

RECRUITING

GSK Investigational Site

Kingsport, Tennessee, 37663, United States

RECRUITING

GSK Investigational Site

Knoxville, Tennessee, 37909, United States

RECRUITING

GSK Investigational Site

Nashville, Tennessee, 37211, United States

RECRUITING

GSK Investigational Site

Corsicana, Texas, 75110, United States

RECRUITING

GSK Investigational Site

Georgetown, Texas, 78628, United States

RECRUITING

GSK Investigational Site

Harlingen, Texas, 785500, United States

RECRUITING

GSK Investigational Site

Houston, Texas, 77081, United States

RECRUITING

GSK Investigational Site

Houston, Texas, 77099, United States

RECRUITING

GSK Investigational Site

Mesquite, Texas, 75149, United States

RECRUITING

GSK Investigational Site

Missouri City, Texas, 77459, United States

RECRUITING

GSK Investigational Site

Pearland, Texas, 77584, United States

RECRUITING

GSK Investigational Site

San Antonio, Texas, 78229, United States

RECRUITING

GSK Investigational Site

Ogden, Utah, 84403, United States

RECRUITING

GSK Investigational Site

Ogden, Utah, 84405, United States

RECRUITING

GSK Investigational Site

Sandy City, Utah, 84070, United States

RECRUITING

GSK Investigational Site

Lynchburg, Virginia, 24502, United States

RECRUITING

GSK Investigational Site

Petersburg, Virginia, 23805, United States

RECRUITING

GSK Investigational Site

Richmond, Virginia, 23226, United States

RECRUITING

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Central Study Contacts

US GSK Clinical Trials Call Center

CONTACT

877-379-3718; GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

CONTACT

+44 (0) 20 89904466; GSKClinicalSupportHD@gsk.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: This is a double-blind study
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 9, 2026
• Study Start: April 8, 2026
• Primary Completion (Estimated): March 9, 2027
• Study Completion (Estimated): July 13, 2027
• Last Updated: June 25, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
• Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Locations

US (110)